» Articles » PMID: 18523135

Activation and Block of the Adult Muscle-type Nicotinic Receptor by Physostigmine: Single-channel Studies

Overview
Journal Mol Pharmacol
Date 2008 Jun 5
PMID 18523135
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The plant-derived acetylcholinesterase inhibitor physostigmine has previously been shown to act on the nicotinic acetylcholine receptor (nAChR) causing either direct activation or potentiation of currents elicited by low concentrations of nicotinic agonists, or, at higher concentrations, channel block. We examined mouse adult-type muscle nAChR activation by physostigmine and found that channel activation by physostigmine exhibits many characteristics common with channel activity elicited by nicotinic agonists. Single-channel conductance was indistinguishable, and mutants known to slow channel closing in the presence of nicotinic agonists had a similar effect in the presence of physostigmine. However, physostigmine is a very inefficacious agonist. The presence of physostigmine did not alter the effective opening rate for a subsaturating dosage of carbachol, suggesting that physostigmine does not interact with the nicotinic agonist binding site. Mutations to a residue (alphaLys125) previously identified as part of the putative binding site for physostigmine reduced the duration of openings elicited by physostigmine, but the effects were generally small and, in most cases, nonsignificant. At higher concentrations, physostigmine blocked channel activity. Block manifested as a reduction in the mean open time and the emergence of a closed state, with a mean duration of 3 to 7 ms. The properties of block were consistent with two equivalent blocking sites per receptor with microscopic binding and unbinding rate constants for physostigmine of 20 microM(-1) s(-1) and 450 s(-1) (K(D) = 23 microM). These observations indicate that physostigmine is able to activate muscle nAChR by interacting with a site other than the nicotinic ligand binding site.

Citing Articles

Sleep-related hypermotor epilepsy associated mutations uncover important kinetic roles of α4β2- nicotinic acetylcholine receptor intracellular structures.

Weltzin M, George A, Lukas R, Whiteaker P PLoS One. 2021; 16(3):e0247825.

PMID: 33657187 PMC: 7928491. DOI: 10.1371/journal.pone.0247825.


Synthesis and Biological Evaluation of Pyrroloindolines as Positive Allosteric Modulators of the α1β2γ2 GABA Receptor.

Blom A, Su J, Repka L, Reisman S, Dougherty D ACS Med Chem Lett. 2020; 11(11):2204-2211.

PMID: 33214830 PMC: 7667864. DOI: 10.1021/acsmedchemlett.0c00340.


Distinctive single-channel properties of α4β2-nicotinic acetylcholine receptor isoforms.

Weltzin M, George A, Lukas R, Whiteaker P PLoS One. 2019; 14(3):e0213143.

PMID: 30845161 PMC: 6405073. DOI: 10.1371/journal.pone.0213143.


Determination of the Residues in the Extracellular Domain of the Nicotinic Subunit Required for the Actions of Physostigmine on Neuronal Nicotinic Receptors.

Jin X, Germann A, Shin D, Akk G, Steinbach J Mol Pharmacol. 2017; 92(3):318-326.

PMID: 28630263 PMC: 5548365. DOI: 10.1124/mol.117.108894.


Isoform-specific mechanisms of α3β4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1.

George A, Bloy A, Miwa J, Lindstrom J, Lukas R, Whiteaker P FASEB J. 2017; 31(4):1398-1420.

PMID: 28100642 PMC: 5349798. DOI: 10.1096/fj.201600733R.


References
1.
Auerbach A, Sigurdson W, Chen J, Akk G . Voltage dependence of mouse acetylcholine receptor gating: different charge movements in di-, mono- and unliganded receptors. J Physiol. 1996; 494 ( Pt 1):155-70. PMC: 1160621. DOI: 10.1113/jphysiol.1996.sp021482. View

2.
Akk G, Steinbach J . Structural elements near the C-terminus are responsible for changes in nicotinic receptor gating kinetics following patch excision. J Physiol. 2000; 527 Pt 3:405-17. PMC: 2270086. DOI: 10.1111/j.1469-7793.2000.t01-2-00405.x. View

3.
Akk G, Milescu L, Heckmann M . Activation of heteroliganded mouse muscle nicotinic receptors. J Physiol. 2005; 564(Pt 2):359-76. PMC: 1464446. DOI: 10.1113/jphysiol.2004.078535. View

4.
Schrattenholz A, Schafer H, Albuquerque E, Maelicke A . Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur J Biochem. 1993; 216(2):671-7. DOI: 10.1111/j.1432-1033.1993.tb18187.x. View

5.
van Dyck C, Newhouse P, Falk W, Mattes J . Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. Arch Gen Psychiatry. 2000; 57(2):157-64. DOI: 10.1001/archpsyc.57.2.157. View